Literature DB >> 28936828

[Efficacy and safety of smiltiorrhizadepsidesal combined with conventional western medicine treatment for stable angina pectoris].

Yuan Li1, Lian-Xin Wang1, Yan-Ming Xie1.   

Abstract

In recent years, Chinese patent medicines such as smiltiorrhizadepsidesal(SMDS) injection are combined with western medicine to achieve good clinical efficacy for stable angina pectoris(SAP). SMDS is prepared by the water-soluble active ingredients extracted from Salvia miltiorrhiza, with the functions of promoting blood circulation, removing blood stasis and activating blood vessels, and it is used to treat type ⅠSAP and type ⅡSAP. The efficacy and safety of SMDS combined with simple routine western medicine for SAP were investigated by searching PubMed, EMbase, the Cochrane Library, CNKI, VIP, WanFang Data and CBM Database. SMDS combined with conventional western medicine treatment showed better efficacy for SAP as compared with western medicine alone, and better than other traditional Chinese medicines(such as Danshen injection and compound Danshen injection) combined with conventional western medicine. It was found that SMDS had a positive role in reducing blood viscosity, atherosclerosis, and improving microcirculation. The reported adverse drug reactions (ADRs) of SMDS combined with conventional western medicine therapy in clinical research were basically the same with ADRs reported by spontaneous reporting system(SRS) warning signals. Overall, SMDS combined with conventional western medicine had low incidence of ADR and no serious ADR occurred for SAP treatment in clinical trials. Currently, some drugs related to cardiovascular diseases such as ascinepazidemaleate injection, sodium succinate, propafenone hydrochloride and papaverine hydrochloride injection combined with SMDS have incompatibility, which should be highly emphasized in clinical use. Copyright© by the Chinese Pharmaceutical Association.

Entities:  

Keywords:  adverse reactions ; combination ; effectiveness ; incompatibility ; safety ; smiltiorrhizadepsidesal(SMDS) ; stable angina pectoris(SAP)

Mesh:

Substances:

Year:  2016        PMID: 28936828     DOI: 10.4268/cjcmm20162403

Source DB:  PubMed          Journal:  Zhongguo Zhong Yao Za Zhi        ISSN: 1001-5302


  1 in total

1.  Adjuvant treatment of coronary heart disease angina pectoris with Chinese patent medicine: A prospective clinical cohort study.

Authors:  Yijia Liu; Zhu Li; Dandan Shen; Yanqi Song; Mengnan Huang; Xiaoxue Xue; Jing Xie; Ziyi Jiao; Shuming Gao; Yilan Xu; Shan Gao; Xianliang Wang; Qiang Xu; Sheng Gao; Chunjie Li; Lin Li; Kaijun Niu; Chunquan Yu
Journal:  Medicine (Baltimore)       Date:  2019-08       Impact factor: 1.889

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.